Received: 3 October 2022
Accepted: 2 May 2023
First Online: 22 May 2023
: This study was approved by the King Hussein Cancer Center Institutional Review Board (NO.: 22 KHCC 101). All methods were carried out in accordance with guidelines and regulations of the aforementioned bodies. All participants read an informed consent form before continuing to complete the questionnaire. The informed consent form included the participants’ right to anonymity, confidentially of their data, right to leave the study, and reassurance that their participation is completely voluntary, is not associated with any kind of short-term benefit or rewards and does not affect the quality of their received care.
: Not applicable.
: The authors declare no competing interests.